| Outcome measures in the clinical Trials | RE-LY | Rocket AF | Aristotle | Engage TIMI AF | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dabigatran (150 mg only) |
Warfarin | RR (95% CI) | Rivaroxaban | Warfarin | HR (95% CI) | Apixaban | Warfarin | HR (95% CI) | Edoxaban (60 mg only) |
Warfarin | HR (95% CI) | |
| Composite of strokes and systemic embolisms | 1.11% | 1.69% | 0.66 (0.53-0.82) | 1.70% | 2.20% | 0.79 (0.66-0.96) | 1.27% | 1.60% | 0.79 (0.66-0.95) | 1.18% | 1.50% | 0.87 (0.73-1.04) |
| Ischemic strokes | 0.92% | 1.20% | 0.76 (0.60-0.98) | 1.34% | 1.42% | 0.94 (0.75-1.17) | 0.97% | 1.05% | 0.92 (0.74-1.13) | 1.25% | 1.25% | 1.00 (0.83-1.19) |
| Hemorrhagic strokes | 0.10% | 0.38% | 0.26 (0.14-0.49) | 0.26% | 0.44% | 0.59 (0.37-0.93) | 0.24% | 0.47% | 0.51 (0.35-0.75) | 0.26% | 0.47% | 0.54 (0.38-0.77) |
| Intracranial hemorrhages | 0.30% | 0.74% | 0.40 (0.27-0.60) | 0.50% | 0.70% | 0.67 (0.47-0.93) | 0.33% | 0.80% | 0.42 (0.30-0.58) | 0.39% | 0.85% | 0.47 (0.34-0.63) |
| Gastrointestinal hemorrhages | 1.51% | 1.02% | 1.50 (1.19-1.89) | 3.20% | 2.20% | --* | 0.76% | 0.86% | 0.89 (0.70-1.15) | 1.51% | 1.23% | 1.23 (1.02-1.50) |
| All-cause mortality | 3.64% | 4.13% | 0.88 (0.77-1.00) | 4.50% | 4.90% | 0.92 (0.82-1.03) | 3.52% | 3.94% | 0.89 (0.80-0.99) | 3.99% | 4.35% | 0.92 (0.83-1.01) |